Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 12, 1999
Issued Date -
N/A
app pub date -
Jun 6, 1995
filing date -
Aug 7, 1992
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully